stockrowAurinia Pharmaceuticals Inc (AUPH) vs Recursion Pharmaceuticals, Inc. (RXRX)
- Aurinia Pharmaceuticals Inc AUPH 16.42 +1.30%
- Recursion Pharmaceuticals, Inc. RXRX 3.52 +0.57%
Aurinia Pharmaceuticals Inc and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Aurinia Pharmaceuticals Inc and Recursion Pharmaceuticals, Inc. are of similar size ($2.2B and $2.2B). Recursion Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.9×. Recursion Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 56.2% against 21.0%. Aurinia Pharmaceuticals Inc has the higher net margin (97.7% vs −697.1%) and the higher return on invested capital (43.0% vs −88.5%). Across the 18 metrics below, Aurinia Pharmaceuticals Inc leads on 14 and Recursion Pharmaceuticals, Inc. on 4.
Valuation
Profitability
| Metric | AUPH | RXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.62% | 29.21% | 68.51% |
| Operating margin | 44.78% | (725.44%) | 0.00% |
| Net margin | 97.68% | (697.13%) | 0.00% |
| Free cash flow margin | 55.02% | (460.89%) | 0.00% |
| Return on equity | 61.42% | (48.72%) | (51.96%) |
| Return on assets | 46.45% | (36.29%) | (46.06%) |
| Return on invested capital | 42.95% | (88.54%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack